tissue plasminogen activator

Summary

Summary: A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to PLASMIN. It has fibrin-binding activity and is immunologically different from URINARY PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. EC 3.4.21.68.

Top Publications

  1. ncbi Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke
    Werner Hacke
    Department of Neurology, Universitat Heidelberg, Heidelberg, Germany
    N Engl J Med 359:1317-29. 2008
  2. ncbi Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study
    Nils Wahlgren
    Department of Neurology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Lancet 369:275-82. 2007
  3. ncbi National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate
    Dawn Kleindorfer
    University of Cincinnati College of Medicine, Department of Neurology, 231 Albert Sabin Way ML 0525, Cincinnati, Ohio 45267 0525, USA
    Stroke 39:924-8. 2008
  4. ncbi Tissue-type plasminogen activator: a historical perspective and personal account
    D Collen
    Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium
    J Thromb Haemost 2:541-6. 2004
  5. ncbi Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene
    Joan Montaner
    Neurovascular Research Laboratory, Stroke Unit, Vall d Hebron Hospital, Barcelona, Spain
    Stroke 34:2851-5. 2003
  6. ncbi NR2D-containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotoxicity
    A Baron
    INSERM U, Cyceron, University of Caen Basse Normandie, Caen, France
    Cell Death Differ 17:860-71. 2010
  7. ncbi The human tissue plasminogen activator-Cre mouse: a new tool for targeting specifically neural crest cells and their derivatives in vivo
    Thomas Pietri
    UMR 144 Compartimentation et Dynamique Cellulaire Centre National de la Recherche Scientifique et Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, France
    Dev Biol 259:176-87. 2003
  8. ncbi Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke
    Joan Montaner
    Cerebrovascular Unit, Vall d Hebron Hospital, Barcelona, Spain
    Circulation 107:598-603. 2003
  9. ncbi Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke
    W M Clark
    Oregon Stroke Center, Portland 97201, USA
    JAMA 282:2019-26. 1999
  10. ncbi Methodology of the Interventional Management of Stroke III Trial
    Pooja Khatri
    Department of Neurology, University of Cincinnati, 231 Albert Sabin Way ML 0525, Cincinnati, OH 45267 0525, USA
    Int J Stroke 3:130-7. 2008

Research Grants

  1. Specialized Program of Translational Research In Acute Stroke at the Partners
    Karen Furie; Fiscal Year: 2007
  2. Antiphospholipid antibodies and lupus: new molecular targets for treatment
    Silvia S Pierangeli; Fiscal Year: 2010
  3. Clotting genetic variant, hormones and venous thrombosis
    Nicholas Smith; Fiscal Year: 2007
  4. MRI of Acute Vascular Injury and Hemorrhagic Transformation in Ischemic Stroke
    Robert A Knight; Fiscal Year: 2010
  5. MRI of Acute Vascular Injury and Hemorrhagic Transformation in Ischemic Stroke
    Robert Knight; Fiscal Year: 2009
  6. Transcranial Sonothrombolysis with Diagnostic Ultrasound
    Thilo Hoelscher; Fiscal Year: 2009
  7. Transcranial Sonothrombolysis with Diagnostic Ultrasound
    Thilo Hoelscher; Fiscal Year: 2010
  8. Interaction of Estrogen and Tissue Plasminogen Activator
    Shaohua Yang; Fiscal Year: 2009
  9. ENDOTHELIAL CELL DIVERSITY DURING FETAL DEVELOPMENT
    Eugene Levin; Fiscal Year: 2001
  10. Interaction of Estrogen and Tissue Plasminogen Activator
    Shaohua Yang; Fiscal Year: 2010

Detail Information

Publications286 found, 100 shown here

  1. ncbi Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke
    Werner Hacke
    Department of Neurology, Universitat Heidelberg, Heidelberg, Germany
    N Engl J Med 359:1317-29. 2008
    ..We tested the efficacy and safety of alteplase administered between 3 and 4.5 hours after the onset of a stroke...
  2. ncbi Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study
    Nils Wahlgren
    Department of Neurology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Lancet 369:275-82. 2007
    ..Under European Union regulations, SITS-MOST was required to assess the safety profile of alteplase in clinical practice by comparison with results in randomised controlled trials...
  3. ncbi National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate
    Dawn Kleindorfer
    University of Cincinnati College of Medicine, Department of Neurology, 231 Albert Sabin Way ML 0525, Cincinnati, Ohio 45267 0525, USA
    Stroke 39:924-8. 2008
    Current US estimates of recombinant tissue plasminogen activator (rt-PA) use have been based either on extrapolation of regional studies or on administrative database estimates, both of which may have inherent biases...
  4. ncbi Tissue-type plasminogen activator: a historical perspective and personal account
    D Collen
    Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium
    J Thromb Haemost 2:541-6. 2004
    ..Genetically modified variants of t-PA have been developed for bolus administration in patients with AMI...
  5. ncbi Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene
    Joan Montaner
    Neurovascular Research Laboratory, Stroke Unit, Vall d Hebron Hospital, Barcelona, Spain
    Stroke 34:2851-5. 2003
    ..barrier disruption, has been implicated in the appearance of hemorrhagic transformation (HT) after tissue plasminogen activator (tPA) treatment in stroke patients...
  6. ncbi NR2D-containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotoxicity
    A Baron
    INSERM U, Cyceron, University of Caen Basse Normandie, Caen, France
    Cell Death Differ 17:860-71. 2010
    ..This study shows that the earlier described pro-neurotoxic effect of tPA is mediated by NR2D-containing NMDAR-dependent extracellular signal-regulated kinase activation, a deleterious effect prevented by synaptic pre-activation...
  7. ncbi The human tissue plasminogen activator-Cre mouse: a new tool for targeting specifically neural crest cells and their derivatives in vivo
    Thomas Pietri
    UMR 144 Compartimentation et Dynamique Cellulaire Centre National de la Recherche Scientifique et Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, France
    Dev Biol 259:176-87. 2003
    ..We have established a new transgenic line expressing the Cre recombinase under the control of the human tissue plasminogen activator promoter (Ht-PA)...
  8. ncbi Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke
    Joan Montaner
    Cerebrovascular Unit, Vall d Hebron Hospital, Barcelona, Spain
    Circulation 107:598-603. 2003
    ..Moreover, MMP inhibitors reduce hemorrhagic transformation (HT) after embolic ischemia in tissue plasminogen activator (t-PA)-treated animals...
  9. ncbi Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke
    W M Clark
    Oregon Stroke Center, Portland 97201, USA
    JAMA 282:2019-26. 1999
    ..This restricts the number of patients who can be treated, since most stroke patients present more than 3 hours after symptom onset...
  10. ncbi Methodology of the Interventional Management of Stroke III Trial
    Pooja Khatri
    Department of Neurology, University of Cincinnati, 231 Albert Sabin Way ML 0525, Cincinnati, OH 45267 0525, USA
    Int J Stroke 3:130-7. 2008
    ..a.) approach to recanalization may be more effective than standard i.v. rt-PA (Activase) alone for moderate-to-large National Institutes of Health Stroke Scale (NIHSS>or=10) strokes, and with a similar safety profile...
  11. ncbi Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investiga
    A Schomig
    Deutsches Herzzentrum, 1 Medizinische Klinik rechts der Isar, Munich, Germany
    N Engl J Med 343:385-91. 2000
    ..of platelet glycoprotein IIb/IIIa receptors produces a greater degree of myocardial salvage than fibrinolysis with an accelerated infusion of alteplase, a tissue plasminogen activator, in patients with acute myocardial infarction.
  12. ncbi Tissue-type plasminogen activator rescues neurones from serum deprivation-induced apoptosis through a mechanism independent of its proteolytic activity
    Geraldine Liot
    INSERM, INSERM Avenir tPA in the working brain, Caen, France Université de Caen Basse Normandie, Caen, France GIP Cyceron, Caen, France
    J Neurochem 98:1458-64. 2006
    ....
  13. ncbi Photoreceptor status after resolved macular edema in branch retinal vein occlusion treated with tissue plasminogen activator
    Tomoaki Murakami
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Sakyo ku, Kyoto 606 8507, Japan
    Am J Ophthalmol 143:171-3. 2007
    To evaluate the integrity of photoreceptors in macular edema (ME) associated with branch retinal vein occlusion after intravitreal tissue plasminogen activator.
  14. ncbi Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis
    K Ouriel
    Department of Vascular Surgery, The Cleveland Clinic Foundation, OH 44195, USA
    J Vasc Interv Radiol 11:295-8. 2000
    ..In an effort to better characterize the complications associated with urokinase (UK) and recombinant tissue plasminogen activator (rt-PA), the clinical course of patients treated for lower extremity vascular occlusions at a single ..
  15. ncbi Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia
    Wenlan Liu
    College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA
    Stroke 40:2526-31. 2009
    A major limitation of tissue plasminogen activator (tPA) thrombolysis for ischemic stroke is the narrow time window for safe and effective therapy...
  16. ncbi Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis
    Maarten G Lansberg
    Stanford Stroke Center, Stanford University Medical Center, Palo Alto, CA 94304 9705, USA
    Stroke 40:2438-41. 2009
    ..European Cooperative Acute Stroke Study (ECASS-3) demonstrated a benefit of treatment with intravenous tissue plasminogen activator (tPA) for acute stroke in the 3- to 4.5-hour time-window...
  17. ncbi Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia
    Kiyoshi Tsuji
    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA
    Stroke 36:1954-9. 2005
    Thrombolytic therapy with tissue plasminogen activator (tPA) in ischemic stroke is limited by increased risks of cerebral hemorrhage and brain injury...
  18. ncbi The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling
    O Nicole
    , UMR CNRS 6551, , UPRES EA 2609, Bd H. Becquerel, Cyeron BP 5229, F-14074 Caen Cedex, France
    Nat Med 7:59-64. 2001
    ..These data provide insight into the regulation of NMDA-receptor-mediated signaling and could initiate therapeutic strategies to improve the efficacy of t-PA treatment in man...
  19. ncbi A graphic reanalysis of the NINDS Trial
    Jerome R Hoffman
    Department of Emergency Medicine, University of California School of Medicine, Los Angeles, CA, USA
    Ann Emerg Med 54:329-36, 336.e1-35. 2009
    ..The initial report of the National Institute of Neurologic Diseases and Stroke (NINDS) trials of tissue plasminogen activator in acute ischemic stroke is an example of this phenomenon.
  20. ncbi Portal vein thrombosis after hematopoietic cell transplantation: frequency, treatment and outcome
    K Kikuchi
    Gastroenterology/Hepatology Section and the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, and the University of Washington School of Medicine, Seattle, WA, USA
    Bone Marrow Transplant 29:329-33. 2002
    ..Prognosis depended on the severity of the underlying VOD and not PVT per se, suggesting that treatments directed solely toward dissolution of portal vein thrombi should be used with caution in this setting...
  21. ncbi Protective efficacy of a plasmid DNA encoding Japanese encephalitis virus envelope protein fused to tissue plasminogen activator signal sequences: studies in a murine intracerebral virus challenge model
    Mundrigri S Ashok
    Department of Biochemistry, Indian Institute of Science, Bangalore 560012, India
    Vaccine 20:1563-70. 2002
    ..report the construction of chimeric DNA vaccine vectors in which secretory signal sequence derived from tissue plasminogen activator (TPA) was fused to the full length (pCMVTE) or 398 amino terminal amino acids (pCMVTdeltaE) of Japanese ..
  22. ncbi Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic
    Manuel Yepes
    Department of Neurology and Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA 30322, USA
    Trends Neurosci 32:48-55. 2009
    ..Here, the best studied pathways of tPA neurotoxicity are discussed along with future directions for a safer use of tPA as a thrombolytic agent in the setting of acute ischemic stroke...
  23. ncbi Male-female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population
    J A Schoenhard
    Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical School, Nashville, TN, USA
    Hum Genet 124:479-88. 2008
    ....
  24. ncbi Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells
    Mariano Hurtado
    Unitat de Recerca Biomedica, Institut de Recerca, Hospital Vall d Hebron, Pg Vall d Hebron 119 129, Barcelona 08035, Spain
    Gut 56:1266-74. 2007
    b>Tissue plasminogen activator (tPA) is the major activator of plasminogen in plasma. This serine protease is overexpressed by exocrine pancreas tumour cells, where it promotes tumour cell proliferation, growth, and invasion...
  25. ncbi The effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels are dependent on environmental context
    Folkert W Asselbergs
    Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands
    Hum Genet 122:275-81. 2007
    ..The present study emphasizes the importance of including environmental factors in genetic analyses to fully comprehend the genetic architecture of a specific trait...
  26. ncbi Neural stem cells rescue nervous purkinje neurons by restoring molecular homeostasis of tissue plasminogen activator and downstream targets
    Jianxue Li
    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 26:7839-48. 2006
    ..We previously identified in nr cerebellum a 10-fold increase in tissue plasminogen activator (tPA) as a key component of the mechanism causing nr PN death...
  27. ncbi Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis
    J M Wardlaw
    Department of Clinical Neurosciences, Western General Hospital, Edinburgh EH4 2XU, Scotland, UK
    Stroke 34:1437-42. 2003
    Recombinant tissue plasminogen activator (rtPA; Actilyse) is not as widely used in clinical practice as it could be. Have new data since 1995 strengthened the evidence sufficiently to justify more widespread use of rtPA?
  28. ncbi Tenascin-C triggers fibrin accumulation by downregulation of tissue plasminogen activator
    Florence Brellier
    Friedrich Miescher Institute for Biomedical Research, Novartis Research Foundation, Basel, Switzerland
    FEBS Lett 585:913-20. 2011
    ..Transcript profiling analysis identified tissue plasminogen activator (tPA) as the most consistently over-expressed gene in all tenascin-C deficient MEFs...
  29. ncbi Tissue plasminogen activator and NMDA receptor cleavage
    Tomasz Matys
    Nat Med 9:371-2; author reply 372-3. 2003
  30. ncbi Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials
    Kennedy R Lees
    Department of Medicine and Therapeutics, Faculty of Medicine, University of Glasgow, Western Infirmary, Glasgow, UK
    Lancet 375:1695-703. 2010
    Early administration of intravenous recombinant tissue plasminogen activator (rt-PA) after ischaemic stroke improves outcome...
  31. ncbi The rewards of nicotine: regulation by tissue plasminogen activator-plasmin system through protease activated receptor-1
    Taku Nagai
    Laboratory of Neuropsychopharmacology, Division of Life Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kanazawa 920 1192, Japan
    J Neurosci 26:12374-83. 2006
    ..Here we show that the tissue plasminogen activator (tPA)-plasmin system regulates nicotine-induced reward and dopamine release by activating protease ..
  32. ncbi Gender-specific correlations of plasminogen activator inhibitor-1 and tissue plasminogen activator levels with cardiovascular disease-related traits
    F W Asselbergs
    Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands
    J Thromb Haemost 5:313-20. 2007
    ..was to examine the correlations between plasma levels of plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (t-PA) and cardiovascular disease-related traits in a general population and whether these correlations ..
  33. ncbi Tissue plasminogen activator in the amygdala is critical for stress-induced anxiety-like behavior
    Robert Pawlak
    Laboratory of Neurobiology and Genetics, The Rockefeller University, 1230 York Avenue, New York, New York 10021, USA
    Nat Neurosci 6:168-74. 2003
    ..These studies support the idea that tPA is critical for the development of anxiety-like behavior after stress...
  34. ncbi The role of tissue plasminogen activator in methamphetamine-related reward and sensitization
    Taku Nagai
    Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsuruma cho, Showa Ku, Nagoya 466 8560, Japan
    J Neurochem 92:660-7. 2005
    In the central nervous system, tissue plasminogen activator (tPA) plays a role in synaptic plasticity and remodeling. Our recent study has suggested that tPA participates in the rewarding effects of morphine by regulating dopamine release...
  35. ncbi Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke
    Andrei V Alexandrov
    Stroke Treatment Team, University of Texas Houston Medical School, Houston 77030, USA
    N Engl J Med 351:2170-8. 2004
    ..that is aimed at residual obstructive intracranial blood flow may help expose thrombi to tissue plasminogen activator (t-PA)...
  36. ncbi Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy
    J P Collet
    Department of Cardiology, Hemostasis Laboratory, Pitie Salpetriere Hospital, Hotel Dieu Hospital, Paris, France
    Arterioscler Thromb Vasc Biol 20:1354-61. 2000
    ..A dynamic study of FITC-recombinant tissue plasminogen activator distribution within the fibrin matrix during the course of fibrinolysis showed that the binding front ..
  37. ncbi The effect of flow on lysis of plasma clots in a plasma environment
    D V Sakharov
    Gaubius Laboratory, TNO Prevention and Health, Leiden, The Netherlands
    Thromb Haemost 83:469-74. 2000
    ..In the case of fibrin-specific lysis, the effect of flow on the speed of fibrinolysis is always beneficial...
  38. ncbi Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atheros
    Harold P Adams
    University of Iowa Carver College of Medicine, USA
    Circulation 115:e478-534. 2007
    ..The intended audience is physicians and other emergency healthcare providers who treat patients within the first 48 hours after stroke. In addition, information for healthcare policy makers is included...
  39. ncbi Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data
    Glenn D Graham
    Albuquerque VA and University of New Mexico School of Medicine, Department of Neurology, VA Medical Center, Albuquerque, NM 87122, USA
    Stroke 34:2847-50. 2003
    Concerns persist regarding the safety of tissue plasminogen activator (tPA) therapy for acute ischemic stroke...
  40. ncbi Ultra-early clot aspiration after lysis with tissue plasminogen activator in a porcine model of intracerebral hemorrhage: edema reduction and blood-brain barrier protection
    K R Wagner
    Department of Neurology, University of Cincinnati College of Medicine, Ohio, USA
    J Neurosurg 90:491-8. 1999
    ..Ultra-early hematoma evacuation (< 4 hours) after intracerebral hemorrhage (ICH) may reduce mass effect and edema development and improve outcome. To test this hypothesis, the authors induced lobar hematomas in pigs...
  41. ncbi Hyperbaric oxygen-induced attenuation of hemorrhagic transformation after experimental focal transient cerebral ischemia
    Zhiyong Qin
    Department of Neurosurgery, University of Michigan, Ann Arbor, MI 48109 2200, USA
    Stroke 38:1362-7. 2007
    An increased risk of hemorrhagic transformation is a major factor limiting the use of tissue plasminogen activator for stroke...
  42. ncbi Tissue plasminogen activator mediated blood-brain barrier damage in transient focal cerebral ischemia in rats: relevance of interactions between thrombotic material and thrombolytic agent
    Timo Kahles
    Department of Neurology, University Hospital, JW Goethe University Frankfurt, Schleusenweg 2 16, ZNN, 60528 Frankfurt Main, Germany
    Vascul Pharmacol 43:254-9. 2005
    ..The results of the present study indicate a major role for thrombus-thrombolytic interaction in focal cerebral ischemia with subsequent increased BBB permeability...
  43. ncbi Fibrinolysis: the key to new pathogenetic mechanisms
    Esther Zorio
    Hospital Universitario La Fe, Centro de Investigacion, Servicio de Cardiología y Servicio de Ginecología Valencia, Spain
    Curr Med Chem 15:923-9. 2008
    ....
  44. ncbi Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke
    Mar Castellanos
    Department of Neurology, Hospital Universitari Doctor Josep Trueta in affiliation with the UAB, Avda Francia s n, Girona 17007, Spain
    Stroke 35:1671-6. 2004
    ..We investigated whether high plasma levels of c-Fn were associated with hemorrhagic transformation (HT) after treatment with tissue plasminogen activator (tPA) in patients with acute stroke.
  45. ncbi Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice
    Mengcheng Luo
    State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China
    J Virol Methods 154:121-7. 2008
    ..In the present study, a DNA vaccine encoding the conserved nucleoprotein (NP) with a tissue plasminogen activator (tPA) signal sequence (ptPAs/NP) was generated, and immune responses were examined in vaccinated mice...
  46. ncbi Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study
    Carsten H Meyer
    Department of Ophthalmology, University of Bonn, Germany
    Acta Ophthalmol 86:490-4. 2008
    To assess the effectiveness of consecutive intravitreal injections of recombined tissue plasminogen activator (rtPA), expansile gas and bevacizumab in eyes with acute subretinal haemorrhage (SRH).
  47. ncbi Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C
    Dong Liu
    Frank P Smith Laboratory for Neuroscience and Neurosurgical Research, Department of Neurosurgery and Division of Neurovascular Biology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 645, Rochester, New York 14642, USA
    Nat Med 10:1379-83. 2004
    Although thrombolytic effects of tissue plasminogen activator (tPA) are beneficial, its neurotoxicity is problematic...
  48. ncbi Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies
    Rao Muralikrishna Adibhatla
    Department of Neurological Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    CNS Neurol Disord Drug Targets 7:243-53. 2008
    ....
  49. ncbi Normobaric hyperoxia and delayed tPA treatment in a rat embolic stroke model
    Nils Henninger
    Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
    J Cereb Blood Flow Metab 29:119-29. 2009
    ..embolic stroke (eMCAO) model, the effects of 100% normobaric hyperoxia (NBO) with delayed recombinant tissue plasminogen activator (tPA) administration on ischemic lesion size and safety were assessed by diffusion- and perfusion (PWI)-..
  50. ncbi Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels
    Folkert W Asselbergs
    Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands
    Genomics 89:362-9. 2007
    b>Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) directly influence thrombus formation and degradation and thereby risk for arterial thrombosis...
  51. ncbi Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage
    Tong Cheng
    Frank P. Smith Laboratory for Neuroscience and Neurosurgical Research, Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York 14642, USA
    Nat Med 12:1278-85. 2006
    Brain hemorrhage is a serious complication of tissue plasminogen activator (tPA) therapy for ischemic stroke...
  52. ncbi Comparison of tissue plasminogen activator administration management between Telestroke Network hospitals and academic stroke centers: the Telemedical Pilot Project for Integrative Stroke Care in Bavaria/Germany
    Heinrich J Audebert
    Department of Neurology, Städtisches Klinikum München GmbH, Klinikum Harlaching, Munchen, Germany
    Stroke 37:1822-7. 2006
    ..Telemedicine may help to extend its use. However, concerns remain whether management and safety of tissue plasminogen activator (tPA) administration after telemedical consultation are equivalent in less experienced hospitals ..
  53. ncbi Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator
    Kenji Yagi
    Department of Neurosurgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
    Stroke 40:626-31. 2009
    Intracerebral hemorrhage, induced by recombinant tissue plasminogen activator (rtPA) in ischemic stroke, is attributable to the increased activity of matrix metalloproteinase-9 (MMP-9)...
  54. ncbi Mast cell stabilization reduces hemorrhage formation and mortality after administration of thrombolytics in experimental ischemic stroke
    Daniel Strbian
    Department of Neurology, Helsinki University Central Hospital, Haartmaninkatu 8, 00290 Helsinki, Finland
    Circulation 116:411-8. 2007
    Thrombolysis with tissue plasminogen activator (tPA) improves stroke outcome, but hemorrhagic complications and reperfusion injury occasionally impede favorable prognosis after vessel recanalization...
  55. ncbi Evolving therapeutic approaches to treating acute ischemic stroke
    Jesse M Weinberger
    Mt Sinai School of Medicine, One Gustave L Levy Place, Box 1139, New York, NY 10029, United States
    J Neurol Sci 249:101-9. 2006
    Stroke contributes significantly to death, disability, and healthcare costs; however, recombinant tissue plasminogen activator (rt-PA) is the only approved thrombolytic therapy for acute ischemic stroke...
  56. ncbi The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels
    Folkert W Asselbergs
    Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands
    Thromb Haemost 96:471-7. 2006
    b>Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) directly influence thrombus formation and degradation and thus risk for arterial thrombosis...
  57. ncbi Fibrinolysis therapy achieved with tissue plasminogen activator and aspiration of the liquefied clot after experimental intracerebral hemorrhage: rapid reduction in hematoma volume but intensification of delayed edema formation
    Veit Rohde
    Department of Neurosurgery, Aachen University, Germany
    J Neurosurg 97:954-62. 2002
    Fibrinolysis therapy accomplished using tissue plasminogen activator (tPA) and aspiration is considered to be a viable alternative to microsurgery and medical therapy for the treatment of deep-seated spontaneous intracerebral hematomas (..
  58. ncbi Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I
    W S Smith
    Department of Neurology, University of California-San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143, USA
    AJNR Am J Neuroradiol 27:1177-82. 2006
    ..of the Merci Retriever for opening intracranial vessels in patients ineligible for intravenous (IV) tissue plasminogen activator (tPA)...
  59. ncbi Induction of posterior vitreous detachment in rabbits by intravitreal injection of tissue plasminogen activator following cryopexy
    L Hesse
    Department of Ophthalmology, Philipps University, Marburg, FRG, Germany
    Exp Eye Res 70:31-9. 2000
    The purpose of this study was to generate intravitreal plasmin after intravitreal injection of tissue plasminogen activator (TPA) and cryopexy, and to assess its proteolytic effect on the vitreoretinal border region...
  60. ncbi A population-based study in Ghana to investigate inter-individual variation in plasma t-PA and PAI-1
    Scott M Williams
    Center for Human Genetics Research, 519 Light Hall, Vanderbilt University Medical School, Nashville, TN 37232 0700, USA
    Ethn Dis 17:492-7. 2007
    ..We have initiated a large-scale population-based study to characterize the genetic architecture of plasma t-PA and PAI-1 in Blacks from Sunyani, Ghana...
  61. ncbi Misdiagnosis of stroke in tissue plasminogen activator-treated patients: characteristics and outcomes
    Phillip A Scott
    Department of Emergency Medicine, University of Michigan, Ann Arbor, MI 48109 0303, USA
    Ann Emerg Med 42:611-8. 2003
    ..We report an evaluation of emergency department misdiagnoses in patients treated with tissue plasminogen activator for acute ischemic stroke.
  62. ncbi Enhancing community delivery of tissue plasminogen activator in stroke through community-academic collaborative clinical knowledge translation
    Phillip A Scott
    Department of Emergency Medicine, University of Michigan, Ann Arbor, MI 48106 0381, USA
    Emerg Med Clin North Am 27:115-36, ix. 2009
    ..Approximately 1% of stroke patients in community settings are receiving tissue plasminogen activator (tPA) therapy 12 years after US Food and Drug Administration approval...
  63. ncbi Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke
    Lars Ehlers
    HTA Unit, Aarhus University Hospital, Olof Palmes Allé 17, 8200 Aarhus N, Denmark
    Stroke 38:85-9. 2007
    ..The aim of this study was to assess the costs and cost-effectiveness of intravenous thrombolysis treatment with alteplase (Actilyse) of acute ischemic stroke with 24-hour in-house neurology coverage and use of magnetic resonance imaging...
  64. ncbi In acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous?
    David M Kent
    Institute for Clinical Research and Health Policy Studies, Department of Medicine, Tufts New England Medical Center, 750 Washington St, Box 63, Boston, Mass 02111, USA
    Stroke 35:1141-6. 2004
    ..We examined whether the occurrence of an asymptomatic intracranial hemorrhage affects functional outcome in patients with acute ischemic stroke (AIS) treated or not treated with recombinant tissue plasminogen activator (rt-PA).
  65. ncbi Arteriographic demonstration of slow antegrade opacification distal to a cerebrovascular thromboembolic occlusion site as a favorable indicator for intra-arterial thrombolysis
    G A Christoforidis
    Department of Radiology, The Ohio State University Medical Center, Columbus, OH 43210, USA
    AJNR Am J Neuroradiol 27:1528-31. 2006
    ....
  66. ncbi Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis
    Michael R Grunwald
    The Russell H Morgan Department of Radiology and Radiological Science, The Johns Hopkins School of Medicine, Blalock 545, 600 N Wolfe Street, Baltimore, Maryland 21287, USA
    J Vasc Interv Radiol 15:347-52. 2004
    ..with catheter-directed thrombolysis with urokinase (UK) and the recombinant agents alteplase (tissue plasminogen activator [TPA]) and reteplase (recombinant plasminogen activator [RPA]) in the treatment of symptomatic deep ..
  67. ncbi A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke
    Sergio Amaro
    Stroke 38:2173-5. 2007
    BACKGROUND AND PURPOSE: Uric acid (UA) increases the neuroprotective effects of recombinant tissue plasminogen activator (rt-PA) in experimental ischemia...
  68. ncbi The Cologne stroke experience: safety and outcome in 450 patients treated with intravenous thrombolysis
    Jan Sobesky
    Max Planck Institute for Neurological Research, University of Cologne, Cologne, Germany
    Cerebrovasc Dis 24:56-65. 2007
    ..Predictors of outcome and safety in intravenous thrombolysis within 3 h in clinical routine is a matter of ongoing debate. Available reports contain small patient numbers or summarize heterogeneous multicenter data...
  69. ncbi Relationship between the door-to-TIMI-3 flow time and the infarct size in patients suffering from acute myocardial infarction: analysis based on the fibrinolysis and subsequent transluminal (FAST-3) trial
    Kazuhiro Watanabe
    Department of Cardiology, Surugadai Nihon University Hospital, Tokyo, Japan
    Circ J 68:280-5. 2004
    ....
  70. ncbi Intravenous thrombolysis in German stroke units before and after regulatory approval of recombinant tissue plasminogen activator
    C Weimar
    Department of Neurology, University of Duisburg Essen, Essen, Germany
    Cerebrovasc Dis 22:429-31. 2006
    Intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) within 3 h after onset of focal cerebral ischemia was approved in Germany in August 2000.
  71. ncbi Intravenous thrombolysis for acute ischemic stroke
    Thomas A Tomsick
    University of Cincinnati Medical Center, Greater Cincinnati and Northern Kentucky Stroke Team, The Neuroscience Institute, Dept of Radiology, The University Hospital, Cincinnati, Ohio 45267 0762, USA
    J Vasc Interv Radiol 15:S67-76. 2004
    ..Herein, is a broad review of the knowledge gained and insights created from studies in which thrombolytic treatment was used in patients with stroke...
  72. ncbi Rescue localized intra-arterial thrombolysis for hyperacute MCA ischemic stroke patients after early non-responsive intravenous tissue plasminogen activator therapy
    Dong Joon Kim
    Department of Diagnostic Radiology, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul, 120-752, South Korea
    Neuroradiology 47:616-21. 2005
    The outcome of patients who show no early response to intravenous (i.v.) tissue plasminogen activator (tPA) therapy is poor...
  73. ncbi A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units
    C Longstaff
    Division of Haematology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK
    J Thromb Haemost 2:1416-21. 2004
    ..of a range of plasminogen activators (PAs) used as thrombolytic agents, including streptokinase, tissue plasminogen activator (tPA) and variants, and urokinase (uPA), both single and two chain forms...
  74. ncbi The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke
    David M Kent
    Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Stroke 37:2957-62. 2006
    Many patients with ischemic stroke eligible for recombinant tissue plasminogen activator (rt-PA) are not treated in part because of the risks and benefits perceived by treating physicians...
  75. ncbi Intravenous or intra-arterial thrombolysis?: it's time to find the right approach for the right patient
    Heinrich P Mattle
    Stroke 38:2038-40. 2007
  76. ncbi Acute stroke management in the elderly
    Neer Zeevi
    Department of Neurology, Hartford Hospital, Hartford, Connecticut, USA
    Cerebrovasc Dis 23:304-8. 2007
    ..We reviewed the management of older patients presenting with acute ischemic stroke (AIS) and assessed the safety and efficacy of recombinant tissue plasminogen activator (rtPA) administration in a community-based setting.
  77. ncbi Frequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials
    Joan Marti-Fabregas
    Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Cerebrovasc Dis 23:85-90. 2007
    To determine the frequency and predictors of symptomatic intracerebral hemorrhage (SICH) in patients treated with recombinant tissue plasminogen activator (rt-PA).
  78. ncbi Angiographic analysis of intravascular thrombus volume in patients with acute ischemic stroke
    Adnan I Qureshi
    Imaging Core Laboratory, Zeenat Qureshi Stroke Research Center, Department of Neurology and Neurosciences, University of Medicine and Dentistry of New Jersey, Newark, USA
    J Endovasc Ther 14:475-82. 2007
    ..To investigate the role that intravascular thrombus volume plays in mechanical thrombectomy and dose-titrated algorithms using pharmaceutical thrombolytic therapies...
  79. ncbi Pharmacological treatment of acute ischemic stroke
    Janet Murphy
    Scripps Mercy Hospital, San Diego, Calif 92103 2180, USA
    Crit Care Nurs Q 26:276-82. 2003
    ..Clin Med. 2001; 1:60-65...
  80. ncbi [Thrombolytic therapy in acute ischemic stroke. Critical analysis of current knowledge]
    Veronica Murray
    Medicinska kliniken, Danderyds sjukhus, Stockholm
    Lakartidningen 101:662-8, 670-3. 2004
    ..Giving priority to new large randomized controlled trials is essential to achieve this knowledge...
  81. ncbi [Staphylokinase--a specific plasminogen activator]
    Elibieta Rozpończyk
    Katedra Biochemii Medycznej, Uniwersytetu Medycznego w Lodzi, Lodz
    Postepy Biochem 52:80-6. 2006
    ..This review will focus on the biochemical and thrombolytic properties of staphylokinase and its derivatives, which would make use of treatment in acute myocardial infarction and other cardiovascular diseases...
  82. ncbi Intra-arterial reteplase compared to urokinase for thrombolytic recanalization in acute ischemic stroke
    R M Sugg
    Department of Neurology, University of Texas-Houston Medical School, Houston, TX, USA
    AJNR Am J Neuroradiol 27:769-73. 2006
    ....
  83. ncbi Direct action on the molecule is one of several mechanisms by which ultrasound enhances the fibrinolytic effects of reteplase
    Bjarne Madsen Härdig
    Department of Clinical Sciences, Lund, Cardiology, Lund University, Lund, Sweden
    Blood Coagul Fibrinolysis 17:105-12. 2006
    ..Although this effect disappeared at moderately higher ultrasound intensity, the pre-exposure of clots to ultrasound of higher intensity induced increased fibrinolytic effects of reteplase solution...
  84. ncbi Fibrinolytic treatment for acute ischaemic stroke
    Avi Mazumdar
    Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
    Expert Opin Pharmacother 7:287-96. 2006
    ..At present, intravenous administration of tissue plasminogen activator within 3 h of symptom onset is the only proven effective treatment for patients with acute ischaemic ..
  85. ncbi Therapy of basilar artery occlusion: a systematic analysis comparing intra-arterial and intravenous thrombolysis
    Perttu J Lindsberg
    Department of Neurology, Neurosciences Program, Biomedicum Helsinki, Helsinki, Finland
    Stroke 37:922-8. 2006
    ....
  86. ncbi Multimodal therapy for the treatment of severe ischemic stroke combining GPIIb/IIIa antagonists and angioplasty after failure of thrombolysis
    Alex Abou-Chebl
    Department of Neurology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Stroke 36:2286-8. 2005
    ..9+/-8.7) and 6 (50%) had an NIHSS < or =4 at discharge. CONCLUSIONS: Multimodal rescue therapy was effective at recanalizing occluded cerebral vessels that failed thrombolysis without an excess risk of ICH...
  87. ncbi Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis
    Jan Arne E Björkman
    Department of Integrative Pharmacology, AstraZeneca R and D, S 431 83 Molndal, Sweden
    Thromb Res 116:519-24. 2005
    ..015), compared to rt-PA alone. These results indicate that an inhibitor of CPU activity may have a beneficial effect in patients undergoing thrombolytic therapy by attaining shorter time to reperfusion and improved coronary patency...
  88. ncbi A pilot study of a new thrombolytic agent for acute ischemic stroke in Taiwan within a five-hour window
    Han Hwa Hu
    Department of Neurology, Taipei Veterans General Hospital, Taiwan
    Stroke 37:918-9. 2006
    ..This study was the first clinical trial in Taiwan of a new thrombolytic agent human tissue urokinase type plasminogen activator (HTUPA) in patients with acute ischemic stroke...
  89. ncbi Safety of routine IV thrombolysis between 3 and 4.5 h after ischemic stroke
    M Uyttenboogaart
    Department of Neurology, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
    J Neurol Sci 254:28-32. 2007
    The administration of tissue plasminogen activator (t-PA) has been proven effective for ischemic stroke within 3 h after onset. A pooled-analysis of six trials showed that intravenous t-PA still improves outcome when given between 3 to 4...
  90. ncbi Thrombolytic therapy in acute ischemic stroke in Asia: The first prospective evaluation
    Nijasri C Suwanwela
    Neurological Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok 10330, Thailand
    Clin Neurol Neurosurg 108:549-52. 2006
    ..However, the experience in Asia is still limited. We report the first prospective case series of thrombolytic therapy in a developing Asian country...
  91. ncbi Revascularization end points in stroke interventional trials: recanalization versus reperfusion in IMS-I
    Pooja Khatri
    Department of Neurology, University of Cincinnati, Ohio, OH 45267 0525, USA
    Stroke 36:2400-3. 2005
    ..We sought to determine their relationship in the Interventional Management of Stroke (IMS) Phase I trial of combined intravenous (IV) and intraarterial (IA) recombinant tissue plasminogen activator.
  92. ncbi [Intravenous tissue plasminogen activator (t-PA) for acute ischemic stroke in a local university hospital]
    Kazuo Takahashi
    Department of Neurology, Hematology and Rheumatology, Shimane University School of Medicine, 89-1 Enya-cho, Izumo-shi, Shimane 693-8501, Japan
    No To Shinkei 57:683-8. 2005
    ..Although five patients died in our study, the cause of death in four patients was not hemorrhagic transformation but deteriorating ischemic infraction. The dose of t-PA that we used may have been safe but a little low for thrombolysis...
  93. ncbi Thrombolysis and neuroprotection in cerebral ischemia
    M Gutierrez
    Cerebrovascular Research Group, Hospital Universitario La Paz, Universidad Autonoma Madrid, Spain
    Cerebrovasc Dis 21:118-26. 2006
    ....
  94. ncbi Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke
    David Tanne
    Stroke Center, Department of Neurology, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel
    Stroke 37:1798-804. 2006
    Early thrombolytic therapy with intravenous recombinant tissue plasminogen activator (rtPA) improves clinical outcome in acute ischemic stroke (AIS), but impaired endogenous fibrinolysis, thrombin generation, and vascular injury may ..
  95. ncbi Efficacy of thrombolytic (rt-PA) therapy in old stroke patients: the Perugia Stroke Unit experience
    Lucilla Parnetti
    Stroke Unit, Department of Neuroscience, University of Perugia, Perugia, Italy
    Clin Exp Hypertens 28:397-404. 2006
    The use of intravenous recombinant tissue plasminogen activator (rt-PA) administered within 3 hrs from symptom onset is beneficial in selected patients independent of age; although oldest patients (> or = 80 years) are excluded a priori...
  96. ncbi Duty cycle dependence of ultrasound enhanced thrombolysis in a human clot model
    Jason M Meunier
    Department of Emergency Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA
    Ultrasound Med Biol 33:576-83. 2007
    Combined ultrasound and tissue plasminogen activator (rt-PA) therapy, or ultrasound enhanced thrombolysis (UET), has been shown to improve recanalization in patients with acute ischemic stroke...
  97. ncbi Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors
    Maarten G Lansberg
    Stanford University, Stanford Stroke Center, Palo Alto, CA 94304, USA
    Cerebrovasc Dis 24:1-10. 2007
    ....
  98. ncbi Influence of gender on outcomes after intra-arterial thrombolysis for acute ischemic stroke
    S H Shah
    Department of Neurology, UCLA Medical Center, USA
    Neurology 66:1745-6. 2006
    ....
  99. ncbi What's the "hyper" in hyperacute stroke? Strategies to improve outcomes in ischemic stroke patients presenting within 6 hours
    Mary Kay Bader
    Mission Hospital, Mission Viejo, CA 92688, USA
    AACN Adv Crit Care 17:194-214. 2006
    ..quot; This category of stroke patients is eligible for treatment using intravenous recombinant tissue plasminogen activator when treated within 3 hours, or interventional treatment options when treated within 6 hours of stroke ..
  100. ncbi Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study
    Michael D Hill
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alta
    CMAJ 172:1307-12. 2005
    ..The rate of symptomatic intracranial hemorrhage was low. Stroke thrombolysis is a safe and effective therapy in actual practice...
  101. ncbi Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry
    Mathew J Reeves
    Michigan State University, East Lansing, USA
    Stroke 36:1232-40. 2005
    ..This article describes key features of acute stroke care from 4 prototype registries in Georgia (Ga), Massachusetts (Mass), Michigan (Mich), and Ohio...

Research Grants83

  1. Specialized Program of Translational Research In Acute Stroke at the Partners
    Karen Furie; Fiscal Year: 2007
    ..cell death, NBO may be a useful adjunctive therapy that extends the narrow (3-hour) time window for IV tissue plasminogen activator (tPA) therapy...
  2. Antiphospholipid antibodies and lupus: new molecular targets for treatment
    Silvia S Pierangeli; Fiscal Year: 2010
    ..There is strong evidence that annexin A2, a receptor for tissue plasminogen activator (tPA) and plasminogen, and toll-like receptor 4 (TLR-4), a receptor for bacterial lipopolysaccharide (..
  3. Clotting genetic variant, hormones and venous thrombosis
    Nicholas Smith; Fiscal Year: 2007
    ..protein C receptor, protein S, antithrombin III, tissue activatable fibrinolysis inhibitor (TAFI), tissue plasminogen activator (TPA), and factors VIII, IX, X, and XlII A and B...
  4. MRI of Acute Vascular Injury and Hemorrhagic Transformation in Ischemic Stroke
    Robert A Knight; Fiscal Year: 2010
    ..Thrombolytic therapy with tissue plasminogen activator (tPA) acts to increase blood flow to the ischemic tissue and is the only approved treatment for acute ..
  5. MRI of Acute Vascular Injury and Hemorrhagic Transformation in Ischemic Stroke
    Robert Knight; Fiscal Year: 2009
    ..Thrombolytic therapy with tissue plasminogen activator (tPA) acts to increase blood flow to the ischemic tissue and is the only approved treatment for acute ..
  6. Transcranial Sonothrombolysis with Diagnostic Ultrasound
    Thilo Hoelscher; Fiscal Year: 2009
    ..contrast agents (UCA) potentiate the effect of sonothrombolysis, without or in combination with tissue Plasminogen Activator (tPA)...
  7. Transcranial Sonothrombolysis with Diagnostic Ultrasound
    Thilo Hoelscher; Fiscal Year: 2010
    ..contrast agents (UCA) potentiate the effect of sonothrombolysis, without or in combination with tissue Plasminogen Activator (tPA)...
  8. Interaction of Estrogen and Tissue Plasminogen Activator
    Shaohua Yang; Fiscal Year: 2009
    The demonstration that recombinant tissue plasminogen activator (rtPA) is useful for acute management is changing the approach to ischemic stroke. However, after more than a decade, the use of tPA therapy remains limited...
  9. ENDOTHELIAL CELL DIVERSITY DURING FETAL DEVELOPMENT
    Eugene Levin; Fiscal Year: 2001
    ..Using tissue plasminogen activator (tPA) expression as an endothelial cell marker, we have found a pattern of progressive and transitory ..
  10. Interaction of Estrogen and Tissue Plasminogen Activator
    Shaohua Yang; Fiscal Year: 2010
    The demonstration that recombinant tissue plasminogen activator (rtPA) is useful for acute management is changing the approach to ischemic stroke. However, after more than a decade, the use of tPA therapy remains limited...
  11. PATHOPHYSIOLOGY OF CHRONIC CEREBRAL VASOSPASM
    Robert MacDonald; Fiscal Year: 2000
    ..Treatment of vasospasm, that includes calcium-channel antagonists, hemodynamic therapy and tissue plasminogen activator, accounts for some of the discrepancy between the number of patients with vasospasm seen ..
  12. LEUKOCYTE ADHESION RECEPTORS AND THROMBOSIS IN STROKE
    David Pinsky; Fiscal Year: 2001
    ..the PAI-1 gene are relatively resistant to ischemic cerebral injury, in contrast to mice lacking the tissue plasminogen activator (tPA)gene...
  13. STRUCTURE-FUNCTION STUDIES ON PLASMINOGEN AND PLASMIN
    Francis Castellino; Fiscal Year: 1990
    ..enzymology, immunochemistry, spectroscopic properties and molecular biology of human plasminogen, tissue plasminogen activator, urokinase, streptokinase and fibrin(ogen)...
  14. NMDA RECEPTOR FUNCTION BY SERINE PROTEASE RECEPTORS
    Stephen Traynelis; Fiscal Year: 2003
    ..serine protease-signaling systems, including precursors to the proteases, thrombin, plasmin, Factor Xa, tissue plasminogen activator (tPaA),urokinase, as well as the brain specific proteases and serpin protease inhibitors...
  15. Cardiovascular Effects of Scutellaria baicelensis
    Chun Su Yuan; Fiscal Year: 2002
    ..separate studies, we observed that quercetin, a plant flavonoid, inhibited endothelin-1 and stimulated tissue plasminogen activator in vascular endothelial cells...
  16. PEPTIDE MEDIATED ENHANCEMENT OF THROMBOLYSIS
    Daniel Lawrence; Fiscal Year: 1999
    ..PAI-1 may also play a major role in the clinical response to thrombolytic therapy with tissue plasminogen activator (tPA)...
  17. Stroke Therapy
    VINOD D LABHASETWAR; Fiscal Year: 2010
    ..Intravenous administration of tissue plasminogen activator (t-PA) is the only FDA-approved therapy to re-establish cerebral blood flow...
  18. REGULATION OF BRAIN THROMBOSIS IN STROKE MODELS
    Berislav Zlokovic; Fiscal Year: 2003
    ..APC was protective in this thromboembolic model in wild type mice and in hypercoagulable mice lacking tissue plasminogen activator (tPA-/-)...
  19. WOUND HEALING ANGIOGENESIS
    Frank Isik; Fiscal Year: 2002
    ..include the plasminogen activator system, which consists of urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA), balanced by plasminogen activator inhibitor-1 (PAI-1), which limits plasmin generation and ..
  20. A Novel Ultrasound Phased Array and Sonication Method for Stroke Treatments
    Kullervo Hynynen; Fiscal Year: 2010
    ..of patients that will have recanalization of the occluded vessel when administrated together with tissue plasminogen activator (tPA)...
  21. CEREBRAL HEMORRHAGE MODEL--MECHANISMS AND TREATMENTS
    Kenneth Wagner; Fiscal Year: 1999
    ..The delayed edema can be markedly reduced, even prevented, by early (4h) lysis of the clot with tissue plasminogen activator (tPA) followed by hematoma aspiration...